4,782 Shares in Guardant Health, Inc. $GH Purchased by Trivium Point Advisory LLC

Trivium Point Advisory LLC bought a new position in shares of Guardant Health, Inc. (NASDAQ:GH) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 4,782 shares of the company’s stock, valued at approximately $249,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Janney Montgomery Scott LLC grew its position in Guardant Health by 277.8% during the second quarter. Janney Montgomery Scott LLC now owns 20,574 shares of the company’s stock worth $1,071,000 after buying an additional 15,128 shares in the last quarter. Signaturefd LLC grew its position in Guardant Health by 50.5% during the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after buying an additional 213 shares in the last quarter. MRA Advisory Group grew its position in Guardant Health by 7.1% during the second quarter. MRA Advisory Group now owns 16,353 shares of the company’s stock worth $851,000 after buying an additional 1,078 shares in the last quarter. Osterweis Capital Management Inc. acquired a new stake in Guardant Health during the first quarter worth about $12,634,000. Finally, Rhumbline Advisers lifted its stake in Guardant Health by 4.9% during the first quarter. Rhumbline Advisers now owns 175,432 shares of the company’s stock worth $7,473,000 after purchasing an additional 8,202 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Guardant Health Trading Up 0.3%

NASDAQ:GH opened at $62.65 on Thursday. Guardant Health, Inc. has a 1 year low of $20.14 and a 1 year high of $68.00. The firm has a 50 day moving average of $56.61 and a 200-day moving average of $49.25. The stock has a market capitalization of $7.81 billion, a P/E ratio of -18.70 and a beta of 1.53.

Guardant Health (NASDAQ:GH) last posted its earnings results on Wednesday, July 30th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.08. The firm had revenue of $232.09 million during the quarter, compared to the consensus estimate of $211.19 million. During the same quarter last year, the firm posted ($0.84) EPS. The business’s revenue was up 31.0% on a year-over-year basis. Guardant Health has set its FY 2025 guidance at EPS. As a group, analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Insider Activity at Guardant Health

In related news, Director Medina Manuel Hidalgo sold 2,165 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $54.16, for a total value of $117,256.40. Following the completion of the transaction, the director owned 851 shares in the company, valued at $46,090.16. The trade was a 71.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Helmy Eltoukhy sold 300,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the completion of the transaction, the chief executive officer owned 2,123,499 shares of the company’s stock, valued at $126,242,015.55. This trade represents a 12.38% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 302,691 shares of company stock valued at $17,981,965 in the last 90 days. 6.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Wolfe Research upgraded shares of Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 price target for the company in a research note on Thursday, September 25th. Wells Fargo & Company assumed coverage on shares of Guardant Health in a research note on Monday, September 22nd. They set an “overweight” rating and a $72.00 price target for the company. BTIG Research set a $80.00 price target on shares of Guardant Health in a research note on Thursday, September 25th. UBS Group raised their price target on shares of Guardant Health from $70.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Finally, Mizuho raised their price target on shares of Guardant Health from $65.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating and twenty-two have assigned a Buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $65.25.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.